Stoke Therapeutics, Inc. (STOK)
25.04
-0.66
(-2.57%)
USD |
NASDAQ |
Oct 23, 16:00
25.03
-0.01
(-0.04%)
After-Hours: 20:00
Stoke Therapeutics Gross Profit Margin (Quarterly) : 87.80% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 87.80% |
| March 31, 2026 | 83.19% |
| December 31, 2025 | 24.75% |
| September 30, 2025 | 90.70% |
| June 30, 2025 | 92.34% |
| March 31, 2025 | 99.32% |
| December 31, 2024 | 95.10% |
| September 30, 2024 | 77.30% |
| June 30, 2024 | 77.02% |
| Date | Value |
|---|---|
| March 31, 2024 | 73.60% |
| December 31, 2023 | 56.64% |
| September 30, 2023 | 63.72% |
| June 30, 2023 | |
| March 31, 2023 | 77.74% |
| December 31, 2022 | 64.76% |
| September 30, 2022 | 68.19% |
| June 30, 2022 | 74.16% |
| March 31, 2022 | 79.20% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Imunon, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -59.88% |
| Return on Assets | -51.96% |
| Return on Invested Capital | -59.25% |
| Profit Margin (Quarterly) | -660.8% |
| Operating Margin (Quarterly) | -701.7% |
| Return on Net Operating Assets | -912.0% |